TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. 18 years of age or older~2. EF \< 40% via echocardiogram within the past 12 months~3. Stable dose of heart failure medications for \> past 1 month~4. NYHA class II - IV~Exclusion Criteria~1. Pregnant or lactating female~2. Receiving IV inotrope~3. History of significant non-compliance~4. Unwilling to adhere to the protocol~5. Systemic systolic BP less than 90 mmHg at screening visit~6. History of allergy to probenecid~7. History of gout~8. History of renal calculi~9. Recent unstable coronary artery syndromes (USA, admission to hospital for AMI, revascularization procedure, or acute decompensated HF requiring hospitalization) within the past 3 months.~10. Implant of CRT device within the past 3 months~11. TIA, CVA or major surgery within the past 3 months~12. Valvular heart disease (more than moderate stenosis or insufficiency)~13. HOCM, myocarditis, constrictive pericarditis, congenital heart disease, 14 Active chemotherapy, significant malignancy or uncontrolled metabolic disease (untreated hyper or hypothyroidism, Cushing's disease etc.)What about uncontrolled DM?? HgA1C \> etc~15. Elevated liver enzymes (\> 3 times ULN), 16. Current atrial fibrillation or frequent PVCs (should we define this now) 17. End stage renal disease (dialysis dependent) or worsening renal insufficiency should define now.~18. History of gastric ulcerations, significant gastroesophageal reflux. 19. Other condition that in the opinion of the investigator, would make the subject a poor candidate for the study.~20. Co-administration of any medication that in the opinion of the investigator places the subject at increased risks due to potential adverse drug interactions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Probenecid (Type: EXPERIMENTAL): Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate therapy.
- placebo (Type: PLACEBO_COMPARATOR): Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate (placebo) therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 years~2. Self-report of ≥3 episodes of emesis occurring in a cyclic pattern for greater than 1 month in the preceding 2 years~3. Current episode \>2 hours of emesis~4. At least one episode of emesis/forceful retching witnessed (including products of emesis at bedside) or heard by an independent observer (healthcare provider or family/friend) in the emergency department~5. Self-reported frequent (near daily to daily x at least 6 months) use of cannabis by inhalation.~6. Working diagnosis of cannabis hyperemesis syndrome in the opinion of the treating emergency physician~Exclusion Criteria:~1. Chronic, daily use of opioid equivalent to ≥10mg morphine/day~2. Inability to comprehend study consent or instructions~3. Unreliable follow-up/unlikely to return for cross-over~4. Administration of an intravenous antiemetic, anticholinergic or antipsychotic (other than up to 100mg dimenhydrinate) in the previous 24 hours~5. Allergy or intolerance to haloperidol or ondansetron~6. Pregnancy~7. Any other medical or psychiatric condition that in the opinion of the enrolling physician would interfere with participation in the trial~8. Current active participation in an investigational drug trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Ondansetron 8mg (Type: ACTIVE_COMPARATOR): 8mg Ondansetron prepared in a 100mL normal saline mini-bag
- Haloperidol 0.05mg/kg (Type: EXPERIMENTAL): 0.05mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag
- Haloperidol 0.1mg/kg (Type: EXPERIMENTAL): 0.1mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Personalized Health Assessment Related to Medications (Project PHARM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Study 1 Inclusion Criteria:~* Provides consent to participate~* Currently enrolled as a student at one of the participating campuses~* Between 18-25 year olds~* Misuse of prescription stimulants in the past year~Study 1 Exclusion Criteria:~* There are no exclusion criteria other than not meeting inclusion criteria.~Study 2 Inclusion Criteria:~* Provides consent to participate~* Currently enrolled as a student at one of the participating campuses and in their second semester/quarter or later~* Has an anticipated graduation date at least 12 months into the future~* Between 18-25 year olds~* Misuse of prescription stimulants in the past year~Study 2 Exclusion Criteria:~* There are no exclusion criteria other than not meeting inclusion criteria.~Study 3 Inclusion Criteria:~* Provides consent to participate~* Previous participation as a Study 2 participant.~Study 3 Exclusion Criteria:~* There are no exclusion criteria other than not meeting inclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Web-Based PFI (Type: EXPERIMENTAL): Participants randomized to the web-based PFI in Study 2 receive a 5 component Personalized Feedback Tool. The first component is presented immediately after the baseline survey and a link to each of the remaining 4 components is sent to participants spaced 1 to 2 weeks apart. The PFI components cover: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol. Each component is comprised of personalized feedback presented in text and graphic format, and each component includes links to tips for making changes if and when the participant is contemplating or ready to commit to change. These tips include general relapse prevention strategies, as well as information about the importance of regular class attendance, study habits, and sleep habits for academic success. General educational tips/strategies for time management, as well as tips for initiating behavior change are also included. Each component takes approximately 5-10 minutes to review.
- Assessment Only (Type: OTHER): The Assessment Only group receives assessment on substance use, health behaviors, and academic behaviors at baseline, 6-month follow-up, and 12-month follow-up in Study 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Inadequate blood sugar control~* No current treatment with other medications to lower blood sugar~Exclusion Criteria:~* Major heart, liver or kidney problems~* Pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin and Metformin (A) (Type: EXPERIMENTAL): PLUS open-label pioglitazone (as needed as rescue medication)
- Saxagliptin and Metformin (B) (Type: EXPERIMENTAL): PLUS open-label pioglitazone (as needed as rescue medication)
- Saxagliptin and Placebo (C) (Type: EXPERIMENTAL): PLUS open-label pioglitazone (as needed as rescue medication)
- Metformin and Placebo (D) (Type: ACTIVE_COMPARATOR): PLUS open-label pioglitazone (as needed as rescue medication)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Xenon as an Adjuvant to Propofol Anaesthesia in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with coronary artery disease scheduled for elective OPCAB-surgery~* patients willing and able to complete the requirements of this study~* Ejection fraction \>30%~Exclusion Criteria:~* Lack of informed consent~* age \< 18 years~* COPD GOLD \>II~* Renal dysfunction defined as serum-creatinine \>1.5mg/dl~* acute coronary syndrome during the last 24 hours; haemodynamic instability, requirement of inotropic support~* single vessel grafting~* disabling neuropsychiatric disorders (severe dementia, Alzheimer's disease, schizophrenia, depression, low preoperative cognitive state (MMSE at baseline \<25), history of stroke with residuals, increased intracranial pressure~* Hypersensitivity to the study medication~* Presumed uncooperativeness or legal incapacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Xenon and propofol (Type: ACTIVE_COMPARATOR): None
- propofol (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged 18 to 80 years.~* Diagnosis of type 2 diabetes mellitus and on a stable regimen of any oral antidiabetic agent(s) for at least 3 months, with or without adjunctive use of Byetta (exenatide);~Note: Subjects diagnosed with type 2 diabetes mellitus who were not on oral antidiabetic agents may have been enrolled if they had a documented history of type 2 diabetes by American Diabetes Association criteria, including the specific plasma glucose results listed below:~* Fasting plasma glucose \>=126 mg/dL (7.0 mmol/L); or~* Symptoms of hyperglycemia and a casual (any time of day without regard to time since last meal) plasma glucose \>=200 mg/dL (11.1 mmol/L). The classic symptoms of hyperglycemia were considered to include polyuria, polydipsia, and unexplained weight loss; or~* Two-hour plasma glucose \>=200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test;~* Newly diagnosed hypertension or uncontrolled hypertension (defined as SBP \>130 mmHg and/or DBP \>80 mmHg) on current antihypertensive monotherapy or combination therapy.~* Subjects must fulfill mean seated office blood pressure parameters at two consecutive, qualifying visits during the placebo run-in phase, and, subsequently, daytime ambulatory blood pressure monitoring (ABPM) criteria.~* Females should not be pregnant or lactating and, if applicable, using adequate contraception.~Exclusion Criteria:~* Subjects with uncontrolled hypertension taking multiple antihypertensive therapies (at the discretion of the investigator).~* Type 2 diabetes mellitus with a glycosylated hemoglobin A1c (HbA1c) \>=9.0% at screening;~* Subjects with type 1 or type 2 diabetes mellitus requiring insulin.~* Subjects with any serious disorder which may limit the ability to evaluate the safety and efficacy of study medication, or subjects with secondary hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- aml + olm + hctz (Type: EXPERIMENTAL): amlodipine; and olmesartan medoxomil, if required; and hydrochlorothiazide, if required.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NovaFerrum® vs Ferrous Sulfate Treatment in Young Children With Nutritional Iron Deficiency Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 9 to \< 48 months~2. IDA documented by hematologic indices (hemoglobin, MCV, RDW, reticulocyte count, reticulocyte hemoglobin content), serum ferritin, serum iron and total iron binding capacity~Exclusion Criteria:~1. Iron deficiency likely or definitely due to blood loss from the intestine or other sites.~2. Evidence of response to recent/current oral iron therapy, as determined by increase in hemoglobin by \> 1.0 gm/dL and MCV by 5 fL above measurements prior to iron therapy~3. History or evidence of intestinal malabsorption~4. History of prior intravenous iron therapy~5. Major co-morbidity such as a serious chronic medical condition unrelated to iron deficiency apparent on history, physical examination, or laboratory tests~6. Other causes of anemia (sickle cell disease, thalassemia, other hemolytic anemia, bone marrow failure, etc.) apparent by history, physical examination, and/or laboratory tests.~7. High likelihood of suboptimal adherence by parents with study requirements (previous missed clinic visits)~8. Inability to tolerate oral medications~9. History of birth at \< 30 weeks gestation~10. Other medical or social factors at discretion of treating physician

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 48 Months
- Healthy Volunteers: f

Study Arms:
- NovaFerrum® (Type: ACTIVE_COMPARATOR): Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks.
- Ferrous Sulfate (Type: ACTIVE_COMPARATOR): Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, ferrous sulfate, for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Understanding Visual Confusion Using Stereoscopic Displays

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Better than 20/40 visual acuity in the worse eye~* No restrictions of the peripheral visual field: (at least 60 degrees vertically and 40 degrees horizontally)~* At least 14 years of age (no upper age limit)~* Able to give voluntary, informed consent~* Able to understand English~* Binocular vision parameters within normal limits (Stereopsis ≤ 100 arc sec on any stereo test)~Exclusion criteria:~* Patients with any physical or mental disabilities, including cognitive dysfunction, balance problems, or other deficits that could impair their ability to respond to the stimuli presented in this study will be excluded~* Being unable to complete sessions lasting 2-3 hours

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Visual confusion (Type: EXPERIMENTAL): Participants viewed peripheral targets in three different visual confusion conditions (three interventions): binocular visual confusion (unilateral opaque target), unilateral monocular visual confusion (unilateral see-through target), and bilateral monocular visual confusion (bilateral see-through target). Each intervention was presented twice in a randomized order, resulting in a total of six trials. During each trial, a peripheral target was presented in front of a forward-moving background for one minute. Participants were instructed to hold down the controller button while the target was visible and release it when a third or more of the target disappeared. After each trial, participants could take a brief break before the next trial in a different visual confusion condition was presented in a randomized order.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with moderate to severe COPD, with a post bronchodilator FEV1 of 40 to 80% of predicted and FEV1/FVC ratio of ≤0.70.~* They must have a baseline increase in FEV1 of \>150 mL following four puffs of salbutamol.~* They must have at least a 10 pack-year smoking history, and may be either a current or former smoker.~Exclusion Criteria:~* Patients must be clinically stable without recent COPD exacerbations or hospitalisations.~* They must not have uncontrolled disease or chronic heart failure.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- RPL554 100 mcg (Type: EXPERIMENTAL): Part A: Patients receive 1 dose of either RPL554 100mcg via metered dose inhaler.~Part B: not applicable
- RPL554 300 mcg (Type: EXPERIMENTAL): Part A: Patients receive 1 dose of RPL554 300mcg via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 300mcg via metered dose inhaler in crossover fashion.
- RPL554 1000 mcg (Type: EXPERIMENTAL): Part A: Patients receive 1 dose of RPL554 1000mcg via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 3000mcg via metered dose inhaler in crossover fashion.
- RPL554 3000 mcg (Type: EXPERIMENTAL): Part A: Patients receive 1 dose of either RPL554 3000mcg via metered dose inhaler.~Part B: Patients receive repeat doses of RPL554 3000mcg via metered dose inhaler in crossover fashion.
- RPL554 6000 mcg (Type: EXPERIMENTAL): Part A: Patients receive 1 dose of either RPL554 6000mcg via metered dose inhaler.~Part B: not applicable
- RPL554 Placebo (Type: PLACEBO_COMPARATOR): Part A: Patients receive 1 dose of RPL554 placebo via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 placebo via metered dose inhaler in crossover fashion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 40 years of age at the time of hospital admission~* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) according to the International Statistical Classification of Diseases and Related Health Problems Version 10 (ICD-10) established by the Health Care Protocol of the Health Secretariat of Federal District (SES/DF), with the following codes:~  * J41.0 - Simple chronic bronchitis~ * J41.1 - Mucopurulent chronic bronchitis~ * J41.8 - Mixed simple and mucopurulent chronic bronchitis~ * J42 - Unspecified chronic bronchitis~ * J43.1 - Panlobular emphysema~ * J43.2 - Centrilobular emphysema~ * J43.8 - Other emphysema~ * J43.9 - Emphysema, unspecified~ * J44.0 - Chronic obstructive pulmonary disease with acute lower respiratory infection~ * J44.1 - Chronic obstructive pulmonary disease with acute exacerbation, unspecified~ * J44.8 - Other specified chronic obstructive pulmonary disease~ * J44.9 - Chronic obstructive pulmonary disease, unspecified~Exclusion Criteria:~* Patients younger than 40 yeas of age at the time of hospital admission

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients diagnosed with COPD, admitted to the hospital with acute exacerbations (Type: None): Patients over 40 years of age, diagnosed with Chronic Obstructive Pulmonary Disease (COPD), admitted to the hospital with acute exacerbations as recorded in the DATASUS (Unified Health Brazilian System Informatics Department (in Portuguese) between August 2017 and July 2019. Patients were treated with either Tiotropium bromide in soft mist inhaler (SPIRIVA® RESPIMAT®) or with Glycopyrronium bromide in dry powder inhaler (Seebri® Breezhaler®) as part of the treatment plan for Chronic Obstructive Pulmonary Disease (COPD) defined by the Health State Secretariat of Distrito Federal (DF) in Brazil.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Population Pharmacokinetics of Benznidazole in Children With Chagas Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children 2 - 12 years old of both sexes, with a diagnosis of Chagas' disease and eligible for treatment with benznidazole, as per current treatment protocols.~* Chagas disease diagnostic criteria: At least 2 positive serological tests for Trypanosoma cruzi infection (ELISA, hemoagglutination, particle agglutination tests).~* Informed consent signed by the parents, and consent or assent of the patients (according to age and consenting capacity).~Exclusion Criteria:~* Patients with a history of hypersensitivity to benznidazole or any of the drug excipients~* Immunocompromised patients~* Altered hepatic function (increase in AST/ALT x3 or bilirubin x3) or altered renal function (increase in creatinine x3)~* Pregnancy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Benznidazole (Type: EXPERIMENTAL): Treatment of pediatric Chagas disease with benznidazole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete